About: Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings
Creator	Pickering, Suzanne Batra, Rahul Edgeworth, Jonathan Malim, Michael Neil, Stuart Sanders, Rogier Douthwaite, Sam Macmahon, Eithne Acors, Sam Betancor, Gilberto Bisnauthsing, Karen Brouwer, Philip Doores, Katie Galão, Graham, Carl Hemmings, Oliver Ik, Kia Kouphou, Neophytos Luptak, Jakub Martinez Nunez, Rocio Mccoy, Laura Merrick, Blair Nebbia, Gaia O'connell, Lorcan O'hara, Geraldine Patel, Amita Rui, Pedro Seow, Jeffrey Signell, Adrian Steel, Kathryn Tan, Mark Van Gils, Marit Wilson, Harry
source	MedRxiv
abstract	There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as a complement to existing diagnostic capabilities and for determining community seroprevalence. We therefore evaluated the performance of a variety of antibody testing technologies and their potential as diagnostic tools. A highly specific in-house ELISA was developed for the detection of anti-spike (S), -receptor binding domain (RBD) and -nucleocapsid (N) antibodies and used for the cross-comparison of ten commercial serological assays - a chemiluminescence-based platform, two ELISAs and seven colloidal gold lateral flow immunoassays (LFIAs) - on an identical panel of 110 SARS-CoV-2-positive samples and 50 pre-pandemic negatives. There was a wide variation in the performance of the different platforms, with specificity ranging from 82% to 100%, and overall sensitivity from 60.9% to 87.3%. However, the head to head comparison of multiple serodiagnostic assays on identical sample sets revealed that performance is highly dependent on the time of sampling, with sensitivities of over 95% seen in several tests when assessing samples from more than 20 days post onset of symptoms. Furthermore, these analyses identified clear outlying samples that were negative in all tests, but were later shown to be from individuals with mildest disease presentation. Rigorous comparison of antibody testing platforms will inform the deployment of point of care technologies in healthcare settings and their use in the monitoring of SARS-CoV-2 infections.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1101/2020.06.02.20120345
has license	medrxiv
sha1sum (hex)	e11e6713c11f4e9cb53c6df757fcabca725db69a
schema:url	https://doi.org/10.1101/2020.06.02.20120345
resource representing a document's title	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings
resource representing a document's body	covid:e11e6713c11f4e9cb53c6df757fcabca725db69a#body_text
is schema:about of	named entity 'multiple' named entity 'assays' named entity 'time' named entity 'identical' named entity 'samples' named entity 'SAMPLES' named entity 'EVALUATED' named entity 'DETECTION' covid:arg/e11e6713c11f4e9cb53c6df757fcabca725db69a named entity 'complement' named entity 'flow' named entity 'lateral' named entity 'technologies' named entity 'negatives' named entity 'However' named entity 'seroprevalence' named entity 'serological' named entity 'ELISAs' named entity 'Short title' named entity 'serological' named entity 'lateral flow assays' named entity 'COVID-19' named entity 'chemiluminescence' named entity 'RBD' named entity 'immunoassays' named entity 'SARS-CoV-2' named entity 'diagnostic tools' named entity 'point-of-care' named entity 'antibody test' named entity 'colloidal gold' named entity 'SARS-CoV-2' named entity 'specificity' named entity 'nucleocapsid' named entity 'TIME' named entity 'COMMERCIAL' named entity '100%' named entity 'POST' named entity 'COMMUNITY' named entity 'SARS-CoV-2' named entity 'antibody testing' named entity 'complement' named entity 'serological' named entity 'antibodies' named entity 'SPECIFICITY' named entity 'NEGATIVES' named entity 'SPECIFIC' named entity 'WAS A' named entity 'COLLOIDAL GOLD' named entity 'LATERAL' named entity 'NUCLEOCAPSID' named entity 'PRE' named entity 'TOOLS' named entity 'ELISA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software